Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.
Hervé Tilly, MD, PhD, professor, Department of Hematology, Centre Henri Becquerel; professor, hematology, University of Rouen, discusses the efficacy of polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) in an Asia subpopulation of patients with diffuse large B-cell lymphoma (DLBCL).
The phase 3 POLARIX trial (NCT03274492) investigated the efficacy and safety of Pola-R-CHP vs rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL. Findings from an Asia subpopulation analysis of the trial were presented at the 2022 EHA Congress.
At a median follow-up of 24.2 months, a statistically significant progression-free survival (PFS) benefit was observed in patients who received Pola-R-CHP compared with those administered R-CHOP, Tilly says. Specifically, the 2-year PFS rate was 74.2% with Pola-R-CHP vs 66.5% with R-CHOP. These data translate to a 36% reduction in the risk of disease progression, relapse, or death in the Pola-R-CHP population, Tilly emphasizes.
The overall survival data from this subpopulation analysis are still maturing, Tilly notes. However, the findings from this analysis were consistent with those of the global study, where event-free survival was observed to be consistent with PFS, indicating a clinical benefit for Pola-R-CHP vs R-CHOP in this subpopulation, Tilly concludes.